Cryo-Cell InternationalSTU:ZCY -2.52%58 Operating Margin % is 9.95% as of Feb. 2026, which is 35% below its 10-year median of 15.29. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €6.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 80.84% on this metric.
Cryo-Cell International Inc operating margin has been in a 5-year decline. The average rate of decline per year is -8.1%.
The historical rank and industry rank for Cryo-Cell International's Operating Margin % or its related term are showing as below:
STU:ZCY'
s Operating Margin % Range Over the Past 10 Years
Min: 10.48 Med: 15.29 Max: 22.49
Current: 14.55
STU:ZCY's Operating Margin % is ranked better than 80.84% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 4.845
vs STU:ZCY: 14.55
Cryo-Cell International's 5-Year Average Operating Margin % Growth Rate was -8.10% per year.
Cryo-Cell International (STU:ZCY) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Cryo-Cell International Operating Margin % Related Terms
Cryo-Cell International Operating Margin % Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs CDIX, EHSI, CCM: Operating Margin % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Operating Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Operating Margin % falls into.
Cryo-Cell International Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cryo-Cell International's Operating Margin % for the fiscal year that ended in Nov. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a Operating Margin % of 9.95% as of Feb. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Cryo-Cell International and its competitors. This is 35% below median its historical median of 15.29. Over the past decade, Cryo-Cell International's Operating Margin % has ranged from 10.48 to 22.49. According to the industry distribution chart, Cryo-Cell International ranks #128 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 19.2%.
Is Cryo-Cell International's Operating Margin % too high?
Cryo-Cell International's current Operating Margin % of 9.95% is 35% below median its 10-year median of 15.29. Over the past 10 years, this metric has ranged from a low of 10.48 to a high of 22.49. The Healthcare Providers & Services industry median Operating Margin % is 4.85. Cryo-Cell International's value of 9.95% is 105.4% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #128 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Operating Margin % compare to CDIX and EHSI?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #128 out of 668 companies for Operating Margin %. This places Cryo-Cell International in the top 19% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 4.85. Cryo-Cell International's value of 9.95% is 105.4% above this benchmark. Historically, Cryo-Cell International's own Operating Margin % has ranged from 10.48 to 22.49 over the past decade. While the company's 10-year median is 15.29 vs. the industry median of 4.85, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Healthcare Providers & Services company?
The median Operating Margin % among Healthcare Providers & Services companies is 4.85, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Operating Margin % of 9.95% is 105.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Operating Margin % is 4.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Operating Margin % is 9.95%, which is 35% below median its own 10-year median of 15.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €6.10, compared to a current price of €3.10 — trading 49.2% below its estimated fair value. The current Operating Margin % is 9.95%, which is 35% below median its 10-year median of 15.29 and 105.4% above the Healthcare Providers & Services industry median of 4.85. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current Operating Margin % is 9.95% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €3.10 is trading 49.2% below its estimated GF Value™ of €6.10.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
Operating Margin %: 9.95% (35% below median its 10-year median of 15.29)
GF Value™: €6.10 vs. price of €3.10 (49.2% below fair value)
Industry Position: 105.4% above the Healthcare Providers & Services median (#128 of 668)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
